{"id":919453,"date":"2025-12-15T02:33:06","date_gmt":"2025-12-15T07:33:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-join-cac-mid-60-and-sbf-120-indices-on-euronext-paris\/"},"modified":"2025-12-15T02:33:06","modified_gmt":"2025-12-15T07:33:06","slug":"nanobiotix-to-join-cac-mid-60-and-sbf-120-indices-on-euronext-paris","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-join-cac-mid-60-and-sbf-120-indices-on-euronext-paris\/","title":{"rendered":"NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris"},"content":{"rendered":"
\n

PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) — \u00a0NANOBIOTIX<\/a> (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company<\/strong>\u2019\u2019), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices.<\/p>\n

These changes will become effective after the market closes on Friday, December 19, 2025.<\/p>\n

The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading listed companies in France. Inclusion in these indices is expected to broaden Nanobiotix\u2019s visibility among institutional investors, strengthen the Company\u2019s presence within European equity markets, and increase exposure to index-linked investment strategies.<\/p>\n

\n \u201cIt is an honor to join the CAC Mid 60 and SBF 120 indices on Euronext Paris,\u201d<\/em> said Laurent Levy, Chief Executive Officer of Nanobiotix. \u201cWe believe this admission reflects the continued confidence of the financial markets in our long-term strategy and the disruptive potential of our nanotherapeutic solutions. As Nanobiotix advances toward key milestones and continues expanding the horizon of physics-based medicine, we remain focused on disciplined execution and creating sustainable value for patients, partners, and shareholders.\u201d<\/em><\/p>\n

\n About NANOBIOTIX<\/strong>\n <\/p>\n

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company\u2019s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.<\/p>\n

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.<\/p>\n

Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.<\/p>\n

For more information about Nanobiotix, visit us at www.nanobiotix.com<\/a> or follow us on LinkedIn<\/a> and Twitter<\/a><\/p>\n

\n Disclaimer<\/strong>\n <\/p>\n

\n This press release contains \u201cforward-looking\u201d statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company\u2019s anticipates its financial resources will be adequate to support operations. Words such as \u201cexpects\u201d, \u201cintends\u201d, \u201ccan\u201d, \u201ccould\u201d, \u201cmay\u201d, \u201cmight\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cshould\u201d and \u201cwill\u201d or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company\u2019 management\u2019s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix\u2019s business and financial performance, which include the risk that assumptions underlying the Company\u2019s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix\u2019s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under \u201cItem 3.D. Risk Factors\u201d, in Nanobiotix\u2019s 2024 universal registration document filed with the AMF on April 2, 2025 under \u201cchapter 1.5 Risk Factors\u201d, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 which are available on the SEC\u2019s website at <\/em>
\n www.sec.gov<\/a>
\n and on the AMF’s website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.<\/em>\n <\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n\n\n
\n Nanobiotix<\/em>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Communications Department<\/strong>
\n
\n Brandon Owens<\/em>
\n
\n VP, Communications<\/em>
\n
+1 (617) 852-4835
contact@nanobiotix.com<\/u><\/td>\n		\n
\n
Investor Relations Department<\/strong>
\n
\n Joanne Choi<\/em>
\n
\n VP, Investor Relations (US)<\/em>
\n
+1 (713) 609-3150
joanne.choi@nanobiotix.com<\/p>\n

Ricky Bhajun<\/em>
Director, Investor Relations (EU)<\/em>
+33 (0) 79 97 29 99
investors@nanobiotix.com<\/p>\n

<\/u><\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n Media Relations<\/em>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
France \u2013 HARDY<\/strong>
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr<\/a> \u2002\u2002<\/td>\n		\n
Global \u2013 uncapped Communications<\/strong>
Becky Lauer
+1 (646) 286-0057
nanobiotixteam@uncappedcommunications.com<\/a><\/td>\n		\u00a0<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n